gi-hepatology oncology
GALAD Model for HCC Diagnosis
GALAD biomarker model for early detection of hepatocellular carcinoma (HCC) in patients with cirrhosis or chronic hepatitis. Combines sex, age, AFP-L3, AFP, and DCP (PIVKA-II).
Score interpretation
GALAD below −0.63 — HCC Less Likely -99–-0.64
Below the conventional cut-off (about 90 % specificity).
→ Continue surveillance per guideline.
GALAD −0.63 or above — HCC More Likely -0.63–99
At or above the conventional cut-off.
→ Multiphase CT or MRI; hepatology / HCC MDT.
Interpretation bands for the GALAD Model. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Maddrey's Discriminant Function for Alcoholic Hepatitis · Hepatology
- Lille Model for Alcoholic Hepatitis · Hepatology
- NAFLD Fibrosis Score · Hepatology
- AST to Platelet Ratio Index (APRI) · Hepatology
- West Haven Criteria for Hepatic Encephalopathy · Hepatology
- EVendo Score for Oesophageal Varices · Hepatology
Drugs
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.